Cart
sales@molnova.com
Sirpiglenastat
CAS No. 2079939-05-0
Sirpiglenastat( —— )
Catalog No. M35655 CAS No. 2079939-05-0
Sirpiglenastat (DRP-104), a glutamine antagonist and prodrug of DON, exhibits antitumor activity by inhibiting glutamine metabolism and stimulating both the innate and adaptive immune systems.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 871 | In Stock |
|
| 5MG | 896 | In Stock |
|
| 10MG | 1207 | In Stock |
|
| 25MG | 1786 | In Stock |
|
| 50MG | 2353 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSirpiglenastat
-
NoteResearch use only, not for human use.
-
Brief DescriptionSirpiglenastat (DRP-104), a glutamine antagonist and prodrug of DON, exhibits antitumor activity by inhibiting glutamine metabolism and stimulating both the innate and adaptive immune systems.
-
DescriptionSirpiglenastat (DRP-104) is a broad acting glutamine antagonist. Sirpiglenastat has anticancer effects by directly targeting tumor metabolism and simultaneously inducing a potent antitumor immune response.
-
In VitroSirpiglenastat (DRP-104) treatment shows broad immune cell modulation effects including increased T, NK, and macrophages. Sirpiglenastat decreases pro-tumorigenic cytokines such as VEGF and KC (IL-8).
-
In VivoCT26 bearing mice treated with Sirpiglenastat (DRP-104) (0.5 mg/kg; s.c.; once a day; for 5 days) shows tumor growth inhibition at day 12 of 90%. Median survival days are 36 days. Sirpiglenastat (0.5 mg/kg; s.c) treatment significantly inhibits tumor growth in the H22 model.Animal Model:CT26 bearing mice Dosage:0.5 mg/kg Administration:s.c.; once a day; for 5 days Result:Showed tumor growth inhibition in mice.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorGlutaminase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2079939-05-0
-
Formula Weight441.48
-
Molecular FormulaC22H27N5O5
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (226.51 mM; Ultrasonic )
-
SMILESC([C@@H](C(N[C@H](C(OC(C)C)=O)CCC(C=[N+]=[N-])=O)=O)NC(C)=O)C=1C=2C(NC1)=CC=CC2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Yumi Yokoyama, et al. DRP-104, a novel broad acting glutamine antagonist, induces distinctive immune modulation mechanisms and synergistic efficacy in combination with immune checkpoint blockade. J Immunother Cancer. 2019 Nov 6;7(Suppl 1):282.?
molnova catalog
related products
-
FLT3-IN-16
FLT3-IN-16 exhibits potent inhibitory activity against FLT3 tyrosine kinase with an IC 50 of 1.1 μM. FLT3-IN-16 can be used for researching acute myeloid leukemia .
-
Shionone
Shionone has anti-tussive and anti-inflammatory effects.
-
NTRC 0066-0
NTRC 0066-0 is an orally available, selective and potent inhibitor of threonine tyrosine kinase (TTK) that inhibits phosphorylation of TTK substrates and induces chromosome missegregation in cell lines and mice for cancer research.
